insitro

insitro is a biotechnology research firm based in South San Francisco, California, founded in 2018 by AI pioneer Daphne Koller.

The company focuses on machine learning and data-driven approaches to drug discovery and development, aiming to create better medicines more efficiently. With around 300 employees, insitro is dedicated to addressing the challenges of drug development by predicting clinical outcomes earlier through its innovative technologies. The company offers drug discovery services and platform licensing to pharmaceutical partners, utilizing its proprietary AI ecosystem. Key technological assets include the Virtual HumanTM AI engine, which analyzes vast datasets to understand disease mechanisms, and the TherMLTM AI Platform, designed to identify genetic drivers for optimal medicine design. Insitro collaborates with major pharmaceutical companies like Bristol Myers Squibb, Eli Lilly, and Gilead, generating revenue through partnerships and platform licensing. The company is advancing a pipeline of therapeutics focused on neuroscience and metabolic diseases, leveraging its advanced data capabilities to enhance drug development processes.